(Q27313709)

English

Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 June 2017

Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study (English)

1 reference

Europe PubMed Central

25 June 2017

prostate cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Trevor M Penning

object named as

Trevor M Penning

18

0 references

Philip W. Kantoff

object named as

Philip W Kantoff

28

0 references

9

object named as

Massimo Loda

1 reference

Europe PubMed Central

25 June 2017

Mary-Ellen Taplin

1

object named as

Mary-Ellen Taplin

1 reference

Europe PubMed Central

25 June 2017

5

object named as

Jerome P Richie

1 reference

Europe PubMed Central

25 June 2017

author name string

Bruce Montgomery

2

1 reference

Europe PubMed Central

25 June 2017

Christopher J Logothetis

3

1 reference

Europe PubMed Central

25 June 2017

Glenn J Bubley

4

1 reference

Europe PubMed Central

25 June 2017

Bruce L Dalkin

6

1 reference

Europe PubMed Central

25 June 2017

Martin G Sanda

7

1 reference

Europe PubMed Central

25 June 2017

John W Davis

8

1 reference

Europe PubMed Central

25 June 2017

Lawrence D True

10

1 reference

Europe PubMed Central

25 June 2017

Patricia Troncoso

11

1 reference

Europe PubMed Central

25 June 2017

Huihui Ye

12

1 reference

Europe PubMed Central

25 June 2017

Rosina T Lis

13

1 reference

Europe PubMed Central

25 June 2017

Brett T Marck

14

1 reference

Europe PubMed Central

25 June 2017

Alvin M Matsumoto

15

1 reference

Europe PubMed Central

25 June 2017

Steven P Balk

16

1 reference

Europe PubMed Central

25 June 2017

Elahe A Mostaghel

17

1 reference

Europe PubMed Central

25 June 2017

Peter S Nelson

19

1 reference

Europe PubMed Central

25 June 2017

Wanling Xie

20

1 reference

Europe PubMed Central

25 June 2017

Zhenyang Jiang

21

1 reference

Europe PubMed Central

25 June 2017

Christopher M Haqq

22

1 reference

Europe PubMed Central

25 June 2017

Daniel Tamae

23

1 reference

Europe PubMed Central

25 June 2017

NamPhuong Tran

24

1 reference

Europe PubMed Central

25 June 2017

Weimin Peng

25

1 reference

Europe PubMed Central

25 June 2017

Thian Kheoh

26

1 reference

Europe PubMed Central

25 June 2017

Arturo Molina

27

1 reference

Europe PubMed Central

25 June 2017

language of work or name

0 references

publication date

13 October 2014

1 reference

Europe PubMed Central

25 June 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

25 June 2017

32

1 reference

Europe PubMed Central

25 June 2017

33

1 reference

Europe PubMed Central

25 June 2017

3705-3715

1 reference

Europe PubMed Central

25 June 2017

Abiraterone in metastatic prostate cancer without previous chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226804

21 March 2017

Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226804

21 March 2017

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226804

21 March 2017

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226804

21 March 2017

Abiraterone and increased survival in metastatic prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226804

7 April 2017

Targeted androgen pathway suppression in localized prostate cancer: a pilot study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226804

28 September 2017

Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226804

28 September 2017

SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226804

28 September 2017

Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226804

28 September 2017

Dihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226804

28 September 2017

From pathogenesis to prevention of castration resistant prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226804

28 September 2017

Novel secondary hormonal therapy in advanced prostate cancer: an update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226804

28 September 2017

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226804

28 September 2017

Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226804

28 September 2017

Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226804

28 September 2017

Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226804

28 September 2017

20-year outcomes following conservative management of clinically localized prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226804

28 September 2017

Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226804

28 September 2017

The face of high risk prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226804

31 May 2018

Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226804

28 November 2018

Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226804

28 November 2018

Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226804

28 November 2018

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4226804

28 November 2018

A Streamlined Three-Dimensional Volume Estimation Method Accurately Classifies Prostate Tumors by Volume

1 reference

https://pubmed.ncbi.nlm.nih.gov/25311217

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results

1 reference

https://pubmed.ncbi.nlm.nih.gov/25311217

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hormonal treatment before radical prostatectomy: a 3-year followup

1 reference

https://pubmed.ncbi.nlm.nih.gov/25311217

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36-month post-treatment PSA results. Canadian Urologic Oncology Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/25311217

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25311217

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2013.53.4578

1 reference

Europe PubMed Central

25 June 2017

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

0 references

1 reference

Europe PubMed Central

25 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q27313709&oldid=1561962951"